Preclinical News and Research

RSS

Researchers in Canada discover novel oncolytic viral therapy against prostate cancer

Researchers in Canada have detected a novel oncolytic viral therapy against prostate cancer with use of a virus called the reovirus, according to study results published in Cancer Research, a journal of the American Association for Cancer Research.

10 Mar 2010

Researchers identify a new mechanism for tumor control

The interaction of a ligand (Neurotrophine-3) and its dependence receptor (TrkC) constitutes a novel mechanism for tumor control in pediatric cancers such as neuroblastoma, and may also be important to the inhibition of other cancers such as breast cancer.

9 Mar 2010

Chimerix initiates CMX001 Phase 2 clinical trial in stem cell transplant patients for CMV

Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced the initiation of a multi-center Phase 2 clinical trial designed to evaluate CMX001 in stem cell transplant recipients who are seropositive for cytomegalovirus (CMV).

9 Mar 2010

Omeros obtains exclusive license to compounds from Asubio Pharma for use in its PDE7 program

Omeros Corporation today announced that it has obtained an exclusive license to compounds from Asubio Pharma Co., Ltd. for use in its PDE7 program, which is focused on the treatment of movement disorders.

9 Mar 2010

Restructuring results in reduction of Exelixis’ workforce by 40% and increases financial strength

Exelixis, Inc. today announced a restructuring as a consequence of its continued strategy to focus resources on the development of its key late-stage compounds. As its first priority, the company will aggressively advance XL184, XL147 and XL765, each of which is the subject of a large clinical development program.

9 Mar 2010

Poniard Pharmaceuticals reports net loss of $13.2M for fourth-quarter 2009

Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today reported financial results for the fourth quarter and year ended December 31, 2009.

8 Mar 2010

Ricerca Biosciences to acquire Discovery and Preclinical business of MDS Pharma Services

Ricerca Biosciences, LLC, announced today the finalization of the acquisition of the Discovery and Preclinical business of MDS Pharma Services with facilities and almost 600 associates in Bothell, Washington; Lyon, France; and Taipei, Taiwan.

8 Mar 2010

Acologix presents preclinical study results of AC-100 on cartilage regeneration at ORS annual meeting

Acologix, Inc., a privately held biopharmaceutical company, today announced the results of its latest preclinical study demonstrating that AC-100, its therapeutic product candidate derived from an endogenous human protein, promotes cartilage regeneration in a large animal model. The data will be presented by Dr. David M. Rosen on March 6, 2010 at the 56th annual meeting of the ORS in New Orleans, LA.

8 Mar 2010

ILS selects Provantis for fully automating toxicology data acquisition, analysis and reporting processes

Instem, a leading provider of early drug development software solutions, announced today that Integrated Laboratory Systems (ILS) has subscribed to Provantis™ Online, enhancing their existing software systems.

6 Mar 2010

Peptimmune granted US patent for PI-2301 peptide copolymer in treatment of multiple sclerosis

Peptimmune, Inc. a privately held biotechnology company, announced today the grant of US Patent Number 7,655,221 (the '221 patent) which protects the target product profile for its PI-2301 peptide copolymer for the treatment of multiple sclerosis, and other autoimmune diseases.

6 Mar 2010

Phase 1 clinical study of ISIS-SOD1Rx in patients with Lou Gehrig's disease commenced

Isis Pharmaceuticals, Inc. announced today that it has initiated a Phase 1 study of ISIS-SOD1Rx in patients with an inherited, aggressive form of Lou Gehrig's disease also known as familial amyotrophic lateral sclerosis (ALS).

5 Mar 2010

Humacyte, Xcellerex collaborate to develop novel vascular graft for transplantation technologies

Humacyte, Inc. and Xcellerex, Inc. have entered into an initial strategic collaboration for Xcellerex to develop a novel manufacturing process that will enable the production of Humacyte’s lead regenerative medicine product using Xcellerex’s XDR single use bioreactor system in its FlexFactory®. Humacyte’s product is a large diameter vascular graft that is based on its innovative and proprietary platform technology for engineering human, extracellular matrix-based tissues that have properties that are similar to native tissues.

5 Mar 2010

Micromet reports total revenues of $4.6M for three months ended December 31, 2009

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the fourth quarter and full year ended December 31, 2009. The Company also highlighted recent pipeline progress and outlined expected 2010 milestones.

4 Mar 2010

Celldex Therapeutics reports net loss of $13.5M for fourth-quarter of 2009

Celldex Therapeutics, Inc. today reported financial results for the fourth quarter and year ended December 31, 2009. Celldex reported a net loss of $13.5 million, or $0.43 per share, for the fourth quarter of 2009 compared to a net loss of $7.5 million, or $0.47 per share, for the fourth quarter of 2008.

4 Mar 2010

Inspire Pharmaceuticals reports net loss of $2.6 million for 2009 fourth quarter

Inspire Pharmaceuticals, Inc. announced today financial results for the fourth quarter and year ended December 31, 2009, reporting a net loss of $2.6 million or ($0.03) per share for the fourth quarter and a net loss of $40.0 million or ($0.60) per share for the full year.

4 Mar 2010

TNFerade's suppression of cancer metastases: Mechanisms revealed

GenVec, Inc. announced the publication of new preclinical research revealing mechanisms by which TNFerade(TM) suppresses cancer metastases through activation of the immune system.

4 Mar 2010

New chemical classes of preclinical compounds identified for Alzheimer’s disease

In an announcement today, Mount Sinai School of Medicine and Medisyn Technologies, Inc. said they have identified new chemical classes of preclinical compounds that may eventually lead to the first effective management of toxic amyloid aggregation and accumulation in the brain— an abnormal biological process long suspected by many researchers to be a major culprit in the onset and progression of Alzheimer’s disease.

4 Mar 2010

"Stem cells in drug discovery and development" workshop to be held during toxicology annual meeting

Cellular Dynamics International (CDI) and Hoffmann-La Roche Inc. (Roche) today announced a workshop to be held during the Society of Toxicology Annual Meeting in Salt Lake City, UT, on March 7 - 11.

3 Mar 2010

Enanta Pharmaceuticals nominates EDP-239 lead development candidate from NS5A HCV inhibitor program

Enanta Pharmaceuticals, Inc. announced today the nomination of lead development candidate, EDP-239, from its NS5A hepatitis C virus (HCV) inhibitor program. EDP-239 has demonstrated picomolar potency against multiple genotypes of the virus and a preclinical pharmacokinetic profile amenable to once-a-day dosing.

3 Mar 2010

PINC trial to test anti-malarial drug in women with DCIS

Can a drug that has been used to treat malaria for years possibly be used to treat breast cancer before it becomes invasive? That's what researchers at George Mason University's Center for Applied Proteomics and Molecular Medicine (CAPMM) and Inova Breast Care Institute (IBCI) are trying to prove.

3 Mar 2010

Preclinical News and Research

Researchers in Canada discover novel oncolytic viral therapy against prostate cancer

Researchers identify a new mechanism for tumor control

Chimerix initiates CMX001 Phase 2 clinical trial in stem cell transplant patients for CMV

Omeros obtains exclusive license to compounds from Asubio Pharma for use in its PDE7 program

Restructuring results in reduction of Exelixis’ workforce by 40% and increases financial strength

Poniard Pharmaceuticals reports net loss of $13.2M for fourth-quarter 2009

Ricerca Biosciences to acquire Discovery and Preclinical business of MDS Pharma Services

Acologix presents preclinical study results of AC-100 on cartilage regeneration at ORS annual meeting

ILS selects Provantis for fully automating toxicology data acquisition, analysis and reporting processes

Peptimmune granted US patent for PI-2301 peptide copolymer in treatment of multiple sclerosis

Phase 1 clinical study of ISIS-SOD1Rx in patients with Lou Gehrig's disease commenced

Humacyte, Xcellerex collaborate to develop novel vascular graft for transplantation technologies

Micromet reports total revenues of $4.6M for three months ended December 31, 2009

Celldex Therapeutics reports net loss of $13.5M for fourth-quarter of 2009

Inspire Pharmaceuticals reports net loss of $2.6 million for 2009 fourth quarter

TNFerade's suppression of cancer metastases: Mechanisms revealed

New chemical classes of preclinical compounds identified for Alzheimer’s disease

"Stem cells in drug discovery and development" workshop to be held during toxicology annual meeting

Enanta Pharmaceuticals nominates EDP-239 lead development candidate from NS5A HCV inhibitor program

PINC trial to test anti-malarial drug in women with DCIS

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News